1
Bisschop, Cornelis, Wind, Thijs T, Blank, Christian U, Koornstra, Rutger H T, Kapiteijn, Ellen, Van den Eertwegh, Alfonsus J M, De Groot, Jan Willem B, Jalving, Mathilde, Hospers, Geke A P
Veröffentlicht in: Bisschop , C , Wind , T T , Blank , C U , Koornstra , R H T , Kapiteijn , E , Van den Eertwegh , A J M , De Groot , J W B , Jalving , M & Hospers , G A P 2019 , ' Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma : Results From the Dutch Expanded Access Program ' , Journal of Immunotherapy , vol. 42 , no. 6 , pp. 208-214 . https://doi.org/10.1097/CJI.0000000000000271;
2019
Veröffentlicht in: Bisschop , C , Wind , T T , Blank , C U , Koornstra , R H T , Kapiteijn , E , Van den Eertwegh , A J M , De Groot , J W B , Jalving , M & Hospers , G A P 2019 , ' Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma : Results From the Dutch Expanded Access Program ' , Journal of Immunotherapy , vol. 42 , no. 6 , pp. 208-214 . https://doi.org/10.1097/CJI.0000000000000271;
2019